ARCHIVES

BRAF Mutation Testing Classifies Indeterminate FNA Samples

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

FDA Oncology Division Invites Advocates To Play Early Role In Cancer Drug Review.

March 23, 2001

FDA Approves Velcade Injection In Mantle Cell Lymphoma

October 31, 2014

FDA Approves Arranon For Leukemia And Lymphoma

December 30, 2005

ODAC Recommends TICE BCG Approval For Recurrent Bladder Cancer Prevention

January 10, 1997

In Brief: Ross, Harvey To Lead Cancer Center Group; NCI Director In Office By Aug. 1, Varmus Says

May 19, 1995

Young Molecular Biologists Optimistic, Survey Finds

February 21, 1997